Zhonghua Zhong Liu Za Zhi. 2025 Jul 23;47(7):617-634. doi: 10.3760/cma.j.cn112152-20250212-00053.
Prostate cancer represents a prevalent malignancy within the male genitourinary system. In recent years, its incidence in China has gradually increased, becoming a significant public health issue. While early detection correlates strongly with improved prognosis, the majority of newly diagnosed prostate cancer patients in China are already in intermediate or advanced stages, precluding curative-intent interventions and contributing to marked survival disparities. The progression of prostate cancer is lengthy, typically encompassing diagnosis, treatment, progression, metastasis, and death, accompanied by a decline in quality of life. Personalized treatment plans should be developed based on the disease stage and patient preferences. In non-metastatic prostate cancer, where the tumor is confined to the prostate, surgery and radiotherapy are the primary treatments, supplemented by neoadjuvant and adjuvant therapies to delay metastasis. For metastatic prostate cancer, systemic therapy is prioritized to prolong survival. In metastatic hormone-sensitive prostate cancer, controlling androgen levels is crucial, while treatment options for metastatic castration resistant prostate cancer are relatively limited, necessitating individualized and precise treatment. During prostate cancer management, prostate-specific antigen levels are closely linked to prognosis and require monitoring. Bone metastasis, the most common site in prostate cancer patients, often triggers skeletal-related events, demanding effective prevention and management. Treatment-related adverse reactions are also a clinical challenge, requiring balanced risk-benefit assessments and judicious drug selection to preserve quality of life. Rapid advancements in screening technologies, surgical innovations, drug development, and China-specific epidemiological factors further complicate decision-making in holistic prostate cancer management. To optimize the standardization of prostate cancer diagnosis and treatment in China, the Genitourinary Oncology Committee of Chinese Anti-cancer Association synthesized global guidelines, clinical evidence and clinical expertise, and addressed critical challenges in the whole-course management of prostate cancer to formulate a multidisciplinary consensus. The expert consensus on whole-course management of prostate cancer (2025 edition) establishes standardized protocols to guide clinical practice, improve treatment outcomes, and enhance patient quality of life.
前列腺癌是男性生殖泌尿系统中一种常见的恶性肿瘤。近年来，其在中国的发病率逐渐上升，成为一个重大的公共卫生问题。虽然早期检测与改善预后密切相关，但中国大多数新诊断的前列腺癌患者已处于中期或晚期，无法进行根治性干预，导致显著的生存差异。前列腺癌的病程漫长，通常包括诊断、治疗、进展、转移和死亡，同时患者生活质量下降。应根据疾病阶段和患者偏好制定个性化的治疗方案。在非转移性前列腺癌中，肿瘤局限于前列腺，手术和放疗是主要治疗方法，并辅以新辅助和辅助治疗以延迟转移。对于转移性前列腺癌，则优先进行全身治疗以延长生存期。在转移性激素敏感性前列腺癌中，控制雄激素水平至关重要，而转移性去势抵抗性前列腺癌的治疗选择相对有限，需要个体化和精准治疗。在前列腺癌管理过程中，前列腺特异性抗原水平与预后密切相关，需要进行监测。骨转移是前列腺癌患者最常见的转移部位，常引发骨相关事件，需要进行有效的预防和管理。治疗相关的不良反应也是一项临床挑战，需要进行风险效益平衡评估并明智地选择药物以维持生活质量。筛查技术、手术创新、药物研发的快速发展以及中国特有的流行病学因素，进一步使前列腺癌整体管理中的决策变得复杂。为优化中国前列腺癌诊断和治疗的标准化，中国抗癌协会泌尿生殖肿瘤专业委员会综合了全球指南、临床证据和临床专业知识，应对前列腺癌全程管理中的关键挑战，制定了多学科共识。《前列腺癌全程管理专家共识（2025版）》建立了标准化方案，以指导临床实践、改善治疗效果并提高患者生活质量。
